Industry Overview - The Russell 2000 Index has reached new highs, indicating a renewed interest in small-cap companies, with an increase of over 13% for the year as market rotation from large-cap stocks accelerates [1][2] - Investors are shifting focus to higher-risk, higher-reward assets, reflecting growing confidence in the economy and corporate sector amid the ongoing US Federal Reserve easing cycle [2][3] - Small caps and penny stocks, previously undervalued, are gaining traction as monetary policy is perceived to be no longer tightening [3][4] Market Sentiment - A third Federal Reserve rate cut and expectations for further easing are driving interest in small companies, with the Russell 2000 Index outperforming the S&P 500 as the year ends [4] - Analysts from major financial institutions anticipate that the rotation towards small-cap stocks will continue into 2026 [4][5] Investment Strategy - The article highlights the methodology for selecting the best multibagger penny stocks, focusing on those trading under $5 with over 100% upside potential and popularity among elite hedge funds [7][8] - The strategy has historically outperformed the market, returning 427.7% since May 2014, significantly beating its benchmark [8] Company Highlights ADC Therapeutics S.A. (NYSE:ADCT) - ADC Therapeutics is identified as a top multibagger penny stock with a current share price of $4.18 and an analyst upside potential of 102.11% [9] - The company has received positive ratings from analysts, with a price target of $10.00 from Guggenheim and $5.00 from RBC Capital based on promising trial data [9][10] - The LOTIS-7 trial results show an overall response rate of 89.8% and a complete response rate of 77.6% for its drug ZYNLONTA, which has received accelerated FDA approval [11][13] Repay Holdings Corporation (NASDAQ:RPAY) - Repay Holdings is another top multibagger penny stock, currently priced at $3.40 with an upside potential of 105.88% [15] - The company is focusing on expanding its market presence and enhancing technology offerings to drive future growth, moving from negative growth and margin pressures [16][17] - Repay Holdings aims to capitalize on the $5.6 trillion market opportunity, particularly in non-discretionary transactions, while achieving over 50% free cash flow [19][20]

Core Viewpoint - ADC Therapeutics SA (ADCT) is identified as a strong momentum stock with a Momentum Style Score of A and a Zacks Rank of 2 (Buy), indicating potential for significant near-term gains [3][4][12]. Momentum Indicators - ADCT shares have increased by 28.57% over the past week, while the Zacks Medical - Biomedical and Genetics industry has remained flat during the same period [6]. - Over the last quarter, ADCT shares rose by 23.68%, and they have surged 123.81% over the past year, significantly outperforming the S&P 500, which increased by only 4% and 14.09% respectively [7]. Trading Volume - The average 20-day trading volume for ADCT is 1,634,451 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the past two months, two earnings estimates for ADCT have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from -$1.68 to -$1.47 [10]. - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating a positive earnings outlook [10].

Group 1: Snowflake Inc (NYSE:SNOW) - Snowflake reported third-quarter revenue of $1.21 billion, exceeding analyst estimates of $1.18 billion [1] - The company achieved adjusted earnings of 35 cents per share, surpassing analyst expectations of 31 cents per share [1] - In pre-market trading, Snowflake shares fell 8.6% to $241.85 [2] Group 2: Other Companies - Net Lease Office Properties (NYSE:NLOP) shares decreased by 14.7% to $25.19 in pre-market trading [4] - Symbotic Inc (NASDAQ:SYM) shares dropped 10.5% to $65.50 following a 10 million share offering announcement [4] - Capricor Therapeutics Inc (NASDAQ:CAPR) shares fell 8.4% to $27.45 after a significant increase of 371% the previous day [4] - ADC Therapeutics SA (NYSE:ADCT) shares declined 8.1% to $3.63 after reporting updated data from its LOTIS-7 trial [4] - Koninklijke Philips NV (NYSE:PHG) shares decreased by 6.8% to $26.11 in pre-market trading [4] - Omeros Corp (NASDAQ:OMER) shares fell 4.2% to $10.18 [4] - Methanex Corp (NASDAQ:MEOH) shares dropped 3.8% to $35.95 [4]

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones increasing by over 250 points, closing up 0.61% at 47,765.87, while the NASDAQ rose 0.07% to 23,430.56, and the S&P 500 gained 0.22% to 6,844.57 [1] - Energy shares saw a notable increase of 1.2%, while information technology stocks fell by 0.6% [1] Company Performance - Macy's Inc reported third-quarter sales of $4.713 billion, a decrease of 0.6% year-over-year, but exceeded analysts' expectations of $4.621 billion. The company also reported adjusted earnings per share of 9 cents [2] Commodity Market - Oil prices rose by 1% to $59.21, gold increased by 0.6% to $4,246.90, silver was up 0.4% to $58.935, and copper saw a significant rise of 3% to $5.4000 [5] European Market - European shares were mostly higher, with the eurozone's STOXX 600 rising by 0.16%, Spain's IBEX 35 Index increasing by 1.55%, while London's FTSE 100 fell slightly by 0.02% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei gaining 1.14%, while Hong Kong's Hang Seng fell by 1.28%, China's Shanghai Composite decreased by 0.51%, and India's BSE Sensex fell by 0.04% [7] Notable Stock Movements - Capricor Therapeutics, Inc. saw a dramatic increase of 291% to $24.87 following positive trial results for its cell therapy [8] - Virax Biolabs Group Limited surged 71% to $0.6709 after announcing clinical progress [8] - Aeva Technologies, Inc. gained 16% to $12.58 after being selected as a LiDAR supplier for a major European OEM [8] - CIMG Inc. shares dropped 35% to $0.1200 due to a reverse stock split announcement [8] - ADC Therapeutics SA fell 29% to $3.2499 after reporting updated trial data [8] - Pure Storage, Inc. decreased by 26% to $69.99 following its third-quarter results [8] Economic Indicators - The S&P Global services PMI declined to 54.1 in November from 54.8, and the composite PMI fell to 54.2 from 54.6 [11] - U.S. industrial production increased by 0.1% month-over-month in September, contrasting with a revised 0.3% decline in August [11] - Private businesses in the U.S. reduced jobs by 32,000 in November, compared to a revised gain of 47,000 in the previous month [11] - U.S. crude oil inventories rose by 0.574 million barrels in the week ending Nov. 28, compared to a 2.774 million barrel gain in the previous week [11]

Group 1 - The article does not provide any specific information or data regarding companies or industries [1]

Core Viewpoint - ADC Therapeutics SA has announced updated results from the LOTIS-7 clinical trial, highlighting the potential of ZYNLONTA in treating DLBCL (Diffuse Large B-cell Lymphoma) [2][3]. Group 1: Clinical Trial Update - The LOTIS-7 clinical trial results were shared in a press release and are available on the company's website [2]. - The Chief Medical Officer, Mohamed Zaki, will provide detailed insights into the LOTIS-7 clinical trial and its updated results during the call [3]. Group 2: Strategic Overview - Ameet Mallik, the Chief Executive Officer, will present a strategic overview and discuss the opportunity for ZYNLONTA in the DLBCL market [3].

Summary of ADC Therapeutics SA Lotus 7 Update Conference Call Company and Industry Overview - **Company**: ADC Therapeutics SA - **Industry**: Oncology, specifically focusing on therapies for Diffuse Large B-Cell Lymphoma (DLBCL) Key Points and Arguments 1. **Clinical Trial Update**: ADC Therapeutics announced updated results from the LOTIS-7 clinical trial, focusing on the combination of Zynlonta and glofitamab for treating DLBCL [2][10] 2. **Zynlonta's Profile**: Zynlonta is positioned as a single-agent therapy for third-line plus DLBCL, with rapid, deep, and durable efficacy, and manageable safety [4][20] 3. **Market Opportunity**: The potential peak revenue for Zynlonta in DLBCL is estimated to be between $500 million and $800 million, with a broader potential reaching $600 million to $1 billion as it expands into earlier lines of therapy and indolent lymphomas [20][21] 4. **Efficacy Data**: The best overall response rate (ORR) in the LOTIS-7 trial was reported at 89.8%, with a complete response (CR) rate of 77.6% among 49 efficacy-available patients [11][12] 5. **Patient Demographics**: The median age of patients in the study was 70 years, with a range from 26 to 85 years, and a median of one prior line of therapy [12][14] 6. **Safety Profile**: Neutropenia was the most common treatment-emergent adverse event, occurring in 32.7% of patients, consistent with known profiles of the individual drugs [11][14][39] 7. **Combination Therapy Rationale**: The combination of Zynlonta and glofitamab is expected to provide additive or synergistic efficacy due to their complementary mechanisms of action [8][10] 8. **Regulatory Strategy**: ADC Therapeutics plans to submit for regulatory approval and compendia listing following positive results from ongoing trials, with updates expected in 2026 [22][23] Additional Important Information 1. **Treatment Landscape**: The DLBCL treatment landscape is evolving, with a current 60/40 split between complex therapies (e.g., CAR-T, bispecifics) and broadly accessible therapies (e.g., ADCs, monoclonal antibodies) [5][6] 2. **Future Catalysts**: Multiple data catalysts are expected in 2026, including updates from LOTIS-5 and LOTIS-7 trials, which could significantly impact Zynlonta's market potential [21][22] 3. **Durability of Responses**: Among patients achieving CR, 33 out of 38 maintained their response as of the data cutoff, indicating promising durability [11][19] 4. **Comparative Efficacy**: The trial showed strong efficacy in both relapsed (100% ORR, 91.6% CR) and primary refractory (80% ORR, 64% CR) patient populations [18][30] 5. **Enrollment Trajectory**: The company is on track to complete enrollment of 100 patients in the LOTIS-7 trial by the first half of 2026, with a focus on maintaining a balanced patient population [43] This summary encapsulates the critical insights from the ADC Therapeutics conference call, highlighting the company's strategic direction, clinical trial outcomes, and market potential in the oncology sector.

LOTIS-7 Clinical Trial Results and Strategy - The LOTIS-7 trial (ZYNLONTA + glofitamab) showed an overall response rate (ORR) of 89.8% (44/49 patients) in 2L+ LBCL patients[37] - The complete response (CR) rate in the LOTIS-7 trial was 77.6% (38/49 patients)[41] - In the LOTIS-7 trial, 6 out of 8 patients previously treated with CAR-T achieved a CR[41] - Grade 3 or higher treatment emergent adverse events (TEAEs) occurred in >5% of patients, including neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%)[40] - Grade 5 AEs occurred in 4.1% (2/49) of patients in the LOTIS-7 trial[40] - Cytokine release syndrome (CRS) of any grade was observed in 36.7% (18/49) of patients in the LOTIS-7 trial[47] Market Opportunity and Revenue Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL and indolent lymphomas[56] - The company believes LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies[17] - The company believes LOTIS-5 has the potential to be the leading regimen for patients who will not receive complex therapies[17] Upcoming Milestones - The company expects full enrollment of 100 patients at selected dose for LOTIS-7 in 1H2026[59] - The company expects to share topline results for LOTIS-5[59]

Core Insights - ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b trial, showing ZYNLONTA® combined with glofitamab (COLUMVI®) achieved an 89.8% overall response rate (ORR) and a 77.6% complete response (CR) rate in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) [1][2] Company Overview - ADC Therapeutics is a global leader in antibody drug conjugates (ADCs), focusing on innovative treatments for patients with hematological malignancies [2] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [2] Clinical Trial Highlights - The LOTIS-7 trial is designed to evaluate the safety and efficacy of ZYNLONTA in combination with various agents, including glofitamab, in patients with B-cell non-Hodgkin lymphoma [1] - As of November 17, 2025, 49 patients were efficacy-evaluable, with a minimum of 6 months follow-up [1] - The trial aims to complete enrollment of approximately 100 patients by the first half of 2026, with full data expected to be shared at a medical meeting and submitted for publication by the end of 2026 [1] Efficacy Data - The best overall response rate (ORR) was 89.8%, with 44 out of 49 patients responding [1] - The complete response (CR) rate was 77.6%, with 33 of the 38 patients who achieved CR remaining in that state at the data cutoff [1] - In the subgroup of 24 relapsed patients, the ORR was 100% and the CR rate was 91.7% [1] - Among 25 primary refractory patients, the ORR was 80% and the CR rate was 64% [1] Safety Profile - The combination treatment was generally well tolerated, with a manageable safety profile [1] - Grade 3 or higher treatment-emergent adverse events (TEAEs) included neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%) [1] - Cytokine release syndrome (CRS) occurred in 36.7% of patients, with varying severity across dose levels [1] Future Plans - The company plans to assess regulatory and compendia strategies for ZYNLONTA and its combinations [1] - ADC Therapeutics is also advancing a next-generation PSMA-targeting ADC, leveraging its expertise in ADC development [2]

Summary of ADC Therapeutics Conference Call Company Overview - ADC Therapeutics is focused on antibody-drug conjugates (ADCs) and is a commercial-stage company with an approved product, Zynlonta, for third-line treatment of diffuse large B-cell lymphoma (DLBCL) [5][6][20] Market Performance - Zynlonta has maintained a stable market share of approximately 10% in the third-line DLBCL setting despite competition from bispecific therapies, which have gained significant market share [7][20] - The DLBCL market is divided into complex therapies (CAR-T and bispecifics) and broadly accessible therapies (ADCs, monoclonal antibodies, and chemotherapy) [6][10] Clinical Trials and Studies - **LOTIS-5 Trial**: A confirmatory study comparing Zynlonta plus rituximab to R-GemOx, with a primary endpoint of progression-free survival (PFS). Top-line results are expected in the first half of 2026 [11][12][20] - **LOTIS-7 Trial**: A study combining Zynlonta with glofitamab, showing promising initial results with an overall response rate of 93% and a complete response (CR) rate of 87% [31][35] Market Opportunities - The third-line DLBCL setting has about 6,000 patients, which could double to over 12,000 in the second-line setting. The potential market opportunity for LOTIS-5 is estimated at $200 million to $300 million [20][21] - The marginal zone lymphoma market presents a significant opportunity with an estimated market potential of $500 million, given the high unmet need and competitive CR rates [24][25] Safety and Efficacy - Zynlonta is characterized by a favorable safety profile, being a fixed-duration, chemo-free therapy with manageable and reversible side effects [18][19] - The company aims to achieve a CR rate of 40% or higher in combination therapies to differentiate itself in the market [16] Financial Position - As of Q3, ADC Therapeutics reported a pro forma cash position of $293 million, providing a runway into at least 2028, which supports the relaunch of Zynlonta and ongoing clinical trials [40] Future Outlook - The company is exploring additional indications for Zynlonta and has a PSMA-directed ADC that is expected to be IND-ready by the end of the year, with plans to seek partnerships for this asset [39] Conclusion - ADC Therapeutics is strategically positioned in the ADC market with a focus on expanding the use of Zynlonta through ongoing clinical trials and exploring new indications, while maintaining a strong financial position to support its growth initiatives [38][40]